Print

Print


Stem cell funds face roadblock
Bill could alter CIRM's focus
San Francisco Business Times - by Ron Leuty

With a $3 billion pot of stem cell research cash in the balance, California 
legislators want to shift money away from politically explosive human 
embryonic stem cells to emerging forms of stem cells.
The provision, an amendment from state Sen. George Runner that was tacked to 
an affordability and accessibility bill, essentially rewrites a section of 
the groundbreaking Proposition 71 and could open a new round of legal 
challenges to the state's stem cell agency, the San Francisco-based 
California Institute for Regenerative Medicine.
At the same time, it also could make it easier for researchers at Stanford 
University, the University of California, San Francisco, the J. David 
Gladstone Institutes and the Children's Hospital Oakland Research Institute 
to score money for their efforts to manipulate adult stem cells into 
embryonic-like stem cells or work with umbilical cord blood cells.
"We just want to make sure the best science is available," said Jana 
Saastad, a spokeswoman for Runner, a Republican from Antelope Valley who has 
been a steadfast opponent of embryonic stem cell research. "That's the 
people's will."

But CIRM and its supporters say Runner's amendment, which the full Assembly 
could take up before its Aug. 22 adjournment, sends an ill-conceived message 
about the future of embryonic stem cells as research and the agency itself 
start to generate results.
"We may be handing a political victory to people opposed to human embryonic 
stem cell research that hasn't been earned and that isn't supported by the 
science," said Jeff Sheehy, a patient advocate and member of CIRM's citizens 
oversight committee. "Symbolism matters."
Prop. 71, which voters approved by a nearly three-to-two margin in 2004, 
called on the state to sell $3 billion in bonds to fund stem cell research. 
That followed President Bush's August 2001 severe restrictions on federally 
funded embryonic stem cell studies because the process requires the 
destruction of human embryos.
In the meantime, Shinya Yamanaka, now a researcher at the Gladstone 
Institutes in San Francisco, and others have induced some adult stem cells 
to change into embryonic-like stem cells. That work has been hailed by 
embryonic stem cell opponents as a better way forward, as well as by those 
looking to sidestep the embryonic stem cell controversy.
Runner's amendment would allow CIRM's scientific and medical research 
funding working group -- which includes 15 scientists who review, score and 
rank grant and loan proposals -- to allow a simple majority vote to push 
forward non-embryonic stem cell research that already could receive federal 
funding.
The group currently requires a two-thirds majority to recommend such 
projects to CIRM's citizens oversight board.

"(The amendment) sends a false message to the rest of the world: 'See, even 
California doesn't put its faith in embryonic stem cell research,'" said Don 
Reed, a member of the Prop. 71 executive committee and co-chairman of the 
advocacy group Californians for Cures.
CIRM has approved funding of some adult and other non-embryonic stem cell 
projects, including more than $19 million for such proposals last month. Its 
emphasis, however, has clearly been on embryonic stem cells.
The agency, stalled for more than two years by legal challenges to Prop. 71, 
has approved $555 million in grants for research and facilities. Embryonic 
stem cell therapies may be five to 10 years off, with companies like Geron 
Corp. in Menlo Park moving forward with potential "cells in a bottle" 
therapies, said CIRM board member Sheehy, but research into manipulated 
adult cells is in its infancy and doesn't appear to offer broad therapies to 
diseases.

"The promise of (embryonic) research is so great that we shouldn't have to 
refight Prop. 71 all over again," Sheehy said.
Runner's amendment, however, could benefit the Gladstone Institutes and the 
Children's Hospital Oakland Research Institute. Gladstone last month 
received more than $3 million from CIRM for induced pluripotent stem cell 
work. Yet CHORI had a $4 million application to fund a therapy lab for 
children with sickle cell anemia and to isolate cord blood cells rejected 
late last year by the science working group.
Bert Lubin, president of CHORI, said CIRM funding should be broader, 
including adult stem cell research that could have an impact on minority 
health issues like sickle cell anemia. National Institutes of Health funding 
is limited, he said, plus CIRM's review process, especially in terms of 
conflicts of interest on the CIRM board, should be resolved.
"I trust the present CIRM administration and feel that they can do this 
without state/political interventions," Lubin said.
Runner amended Senate Bill 1565, which Santa Monica Democrat Sheila Kuehl 
cosponsored, to ensure affordable access for uninsured Californians to 
products and treatments that CIRM funds.
The bill also wants the bipartisan, independent state oversight agency, the 
Little Hoover Commission, to study perceived conflicts of interest within 
CIRM and suggest changes by mid-2009.
In short, Kuehl's bill takes CIRM policies regarding affordability and 
access and turns them into law, said John Simpson, stem cell project 
director with California Watchdog, a taxpayer rights group based in Santa 
Monica.
"That's some sort of payback to the people who are paying for and funding 
this sort of stuff," Simpson said.
CIRM leaders say they have worked well with Kuehl to adjust the bill to 
allow flexibility for treatments that cost a lot to develop but may have a 
smaller patient population than diabetes and other more-common diseases.
But Runner's amendment is "the line in the sand," said Sue North, CIRM's 
director of government relations.
"The issue for us is, the voters believed they were giving priority to stem 
cell research not funded under federal policy," North said. "The Bush 
Administration is still the Bush Administration. The federal policy has not 
changed."

[log in to unmask] / (415) 288-4939

Rayilyn Brown
Director AZNPF
Arizona Chapter National Parkinson Foundation
[log in to unmask] 

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn